GENE ONLINE|News &
Opinion
Blog

2021-10-14| Special

Apnimed’s Oral Drug for Obstructive Sleep Apnea Registers Encouraging Outcomes in Two Phase 2 Trials

by Rajaneesh K. Gopinath
Share To
Sleep apnea is a serious disorder characterized by repeated breathing interruptions during sleep. Among the many types of sleep apnea, obstructive Sleep Apnea (OSA) is the most common, affecting 17% of women and 34% of men in the US. The disorder is often underdiagnosed and is estimated to affect more than 25 million Americans.

OSA occurs when throat muscles intermittently relax after sleep and cause partial or complete upper airway closure. As a result, blood oxygen levels get lowered, and the brain briefly wakes patients from their slumber. This often leads to poor sleep and aggravates other medical conditions such as hypertension, diabetes, cardiovascular disease, and stroke. Besides, impaired sleep also affects work productivity, reduces functional ability, and lowers the quality of life.

Cambridge, MA-based Apnimed is a clinical-stage company that aims to develop novel therapies for sleep apnea and related disorders. On October 13th, the company announced top-line results from two Phase 2 trials, APC-003 and APC-004, evaluating AD109, its investigational, oral medicine for patients with OSA.

GO Prime with only $1.49 now

LATEST
Novel RAGE Antagonist Stirs Hopes for Countering Diabetic Complications
2021-12-07
AstraZeneca Blocks Private Equity Buyout of Swedish Pharma Sobi
2021-12-06
Coherent Biopharma, WuXi STA Collab Takes a Crack at Peptide-Drug Conjugates
2021-12-06
How CDMOs are Restructuring the Biopharma Landscape – An Interview with Bobby Sheng
2021-12-06
BeiGene launches IPO on Shanghai’s STAR market to raise $3B
2021-12-03
Novartis, UCB Take Aim at Parkinson’s Disease Under $1.65 Billion Collab
2021-12-03
Atara Biotherapeutics’ First-In-Class Allogeneic T-Cell Therapy Accepted for EMA Review
2021-12-02
EVENT
2021-12-13
63rd ASH ANNUAL MEETING AND EXPOSITION
Georgia, USA
2021-12-28
BIOHK2021
Hong Kong, China
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!